CBD shows promise in opioid recovery: major trial underway
NCT ID NCT06940674
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether adding cannabidiol (CBD) to standard opioid addiction treatment can reduce cravings and prevent relapse. About 450 adults with opioid use disorder who are already on methadone or buprenorphine will receive CBD or a placebo for 24 weeks. The goal is to see if CBD helps them stay opioid-free longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER (OUD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CODA Treatment Recovery
RECRUITINGPortland, Oregon, 97214, United States
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A bold community experiment takes on the opioid crisis
- Can daily text messages help curb opioid cravings and ease chronic pain?
- Jail-Based PTSD therapy could curb overdose deaths after release
- New pill for opioid addiction heads to first human tests
- Can a daily text help beat opioid addiction? new study aims to find out.
- Can we help people safely stop opioid addiction meds? major study tests new strategies